EP1667686A1 - Association d'inhibiteurs de recaptage de la serotonine et d'inhibiteurs de recaptage de la noradrenaline - Google Patents
Association d'inhibiteurs de recaptage de la serotonine et d'inhibiteurs de recaptage de la noradrenalineInfo
- Publication number
- EP1667686A1 EP1667686A1 EP04769269A EP04769269A EP1667686A1 EP 1667686 A1 EP1667686 A1 EP 1667686A1 EP 04769269 A EP04769269 A EP 04769269A EP 04769269 A EP04769269 A EP 04769269A EP 1667686 A1 EP1667686 A1 EP 1667686A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- alkyl
- halogen
- optionally substituted
- reuptake inhibitor
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Definitions
- This invention is directed to a pharmaceutical compositions comprising a serotonin reuptake inhibitor or pharmaceutically acceptable salts thereof and a norepinephrine reuptake inhibitor or pharmaceutically acceptable salts thereof, and to methods of treatment with such a composition.
- the serotonin reuptake inhibitor is sertraline or a pharmaceutically acceptable salt thereof
- the norepinephrine reuptake inhibitor is [S,S]-reboxetine or a pharmaceutically acceptable salt thereof, wherein sertraline is present in an amount sufficient for dopamine reuptake inhibition, wherein the amount of sertraline is from about 150 mg to about 200 mg.
- the acids which are used to prepare the pharmaceutically acceptable acid salts of the active compounds used in formulating the pharmaceutk cal compositions of this invention that are basic in nature are those which form non-toxi ⁇ c acid addition salts, i.e., salts containing pharmacologically acceptable anions.
- the amount of the norepinephrine reuptake inhibitor or pharmaceutically acceptable salt thereof is preferably an amount effective in enhancing noradrenergic neurotransmission in a mammal.
- the amount of the serotonin reuptake inhibitor is an amount sufficient for dopamine reuptake inhibition.
- Affinity for the sertraline transporter (SERT) and for DAT transporter is determined by the amount of the ⁇ -CIT ligand that is displaced.
- the extent of dopamine reuptake inhibition, measured by transporter displacement using ⁇ -CIT in combination with extracellular dopamine increase, is greater than the extent of placebo.
- Another exemplary daily dose of the norepinephrine reuptake inhibitor is from about 25 mg to about 200 mg of maprotiline per unit dose, preferably between 50 mg and 150 mg of maprotiline per unit dose, which could be administered, for example 1 to 3 times per day.
- An exemplary dose ratio by weight of a serotonin reuptake inhibitor to a norepinephrine reuptake inhibitor combination formulation for oral, parenteral or buccal administration to the average adult human for the treatment of the conditions referred to above is from about 0.00005 to about 20,000, preferably from about 0.25 to about 2,000.
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Dans un mode de réalisation, l'invention concerne des compositions pharmaceutiques et des méthodes pour traiter la dépression chez un mammifère. Un mammifère nécessitant un tel traitement se voit administrer: (i) au moins un inhibiteur de recaptage de la sérotonine ou bien son sel pharmaceutiquement acceptable; et (ii) au moins un inhibiteur de recaptage de la noradrénaline ou bien son sel pharmaceutiquement acceptable. L'inhibiteur de recaptage de la noradrénaline est choisi dans le groupe comprenant la Structure II, la Structure III, et la Structure IV telles que définies dans le présent fascicule .
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50127503P | 2003-09-09 | 2003-09-09 | |
US53889804P | 2004-01-23 | 2004-01-23 | |
US54069604P | 2004-01-30 | 2004-01-30 | |
US10/769,018 US20050014848A1 (en) | 2002-01-23 | 2004-01-30 | Combination of serotonin reuptake inhibitors and norephinephrine reuptake inhibitors |
US10/860,721 US20050009927A1 (en) | 2002-01-23 | 2004-06-03 | Combination of serotonin reuptake inhibitors and norepinephrine reuptake inhibitors |
PCT/IB2004/002864 WO2005023265A1 (fr) | 2003-09-09 | 2004-09-02 | Association d'inhibiteurs de recaptage de la serotonine et d'inhibiteurs de recaptage de la noradrenaline |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1667686A1 true EP1667686A1 (fr) | 2006-06-14 |
Family
ID=34280166
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP04769269A Withdrawn EP1667686A1 (fr) | 2003-09-09 | 2004-09-02 | Association d'inhibiteurs de recaptage de la serotonine et d'inhibiteurs de recaptage de la noradrenaline |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1667686A1 (fr) |
BR (1) | BRPI0413726A (fr) |
CA (1) | CA2542339A1 (fr) |
MX (1) | MXPA06002778A (fr) |
NL (1) | NL1026989C2 (fr) |
TW (1) | TW200526197A (fr) |
WO (1) | WO2005023265A1 (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ556779A (en) | 2002-12-27 | 2008-12-24 | Otsuka Pharma Co Ltd | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
AR042806A1 (es) | 2002-12-27 | 2005-07-06 | Otsuka Pharma Co Ltd | Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo |
WO2006000903A2 (fr) * | 2004-06-09 | 2006-01-05 | Pfizer Limited | Utilisation |
WO2014078568A1 (fr) | 2012-11-14 | 2014-05-22 | The Johns Hopkins University | Méthodes et compositions pour le traitement de la schizophrénie |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1499309A4 (fr) * | 2002-04-24 | 2008-05-28 | Cypress Bioscience Inc | Prevention et traitement de troubles somatiques fonctionnels, y-compris les troubles lies au stress |
-
2004
- 2004-09-02 WO PCT/IB2004/002864 patent/WO2005023265A1/fr not_active Application Discontinuation
- 2004-09-02 BR BRPI0413726-4A patent/BRPI0413726A/pt not_active IP Right Cessation
- 2004-09-02 CA CA002542339A patent/CA2542339A1/fr not_active Abandoned
- 2004-09-02 MX MXPA06002778A patent/MXPA06002778A/es not_active Application Discontinuation
- 2004-09-02 EP EP04769269A patent/EP1667686A1/fr not_active Withdrawn
- 2004-09-08 TW TW093127197A patent/TW200526197A/zh unknown
- 2004-09-08 NL NL1026989A patent/NL1026989C2/nl not_active IP Right Cessation
Non-Patent Citations (1)
Title |
---|
See references of WO2005023265A1 * |
Also Published As
Publication number | Publication date |
---|---|
CA2542339A1 (fr) | 2005-03-17 |
NL1026989A1 (nl) | 2005-03-10 |
MXPA06002778A (es) | 2006-06-14 |
NL1026989C2 (nl) | 2006-01-10 |
BRPI0413726A (pt) | 2006-11-07 |
WO2005023265A1 (fr) | 2005-03-17 |
TW200526197A (en) | 2005-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI298255B (en) | Use of optically pure (s.s)-reboxetine in the manufacture of a medicament for the treatment or prevention of fibromyalgia or another somatoform disorder | |
US6476078B2 (en) | Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction | |
US5708035A (en) | Methods of use and compositions of R(-) fluoxetine | |
JP5431136B2 (ja) | 薬剤を製造するためのミルナシプランの(1s,2r)エナンチオマーの使用 | |
NZ264774A (en) | Use of fluoxetine, venlafaxine, milnacipran and duloxetine with a synergist in pharmaceutical compositions | |
JP2003523382A (ja) | 新規な薬物の組合せ | |
PL219671B1 (pl) | Zastosowanie enancjomeru (1S, 2R) milnacypranu do wytwarzania leku | |
JP5491475B2 (ja) | ムスカリン性受容体m1拮抗剤を使用する精神状態の処置 | |
US20050014848A1 (en) | Combination of serotonin reuptake inhibitors and norephinephrine reuptake inhibitors | |
KR20070051770A (ko) | 자살경향성의 예방 또는 감소 및 자살경향성과 연관된 주요우울증의 치료를 위한 메만틴 | |
AU2011313814B2 (en) | Combination therapy for the treatment of depression and other non-infectious diseases | |
EP0759299B1 (fr) | Potentialisation de la sérotonine | |
EP0386117B1 (fr) | Traitement du syndrome de phase luteale tardive ou premenstruelle | |
US5958429A (en) | Potentiation of serotonin response | |
TW200835477A (en) | Methods for treating depression | |
US20050009927A1 (en) | Combination of serotonin reuptake inhibitors and norepinephrine reuptake inhibitors | |
JP2013079277A (ja) | ムスカリン性受容体m1拮抗薬による肥満の処置 | |
PROFILE | Pharmacology of antidepressants: focus on nefazodone | |
EP1667686A1 (fr) | Association d'inhibiteurs de recaptage de la serotonine et d'inhibiteurs de recaptage de la noradrenaline | |
JP2005513105A (ja) | 臨床的うつ病を治療するためのデオキシペガニンの使用 | |
RU2455981C2 (ru) | Лечение ожирения антагонистами мускаринового рецептора м1 | |
WO1992013452A1 (fr) | Procedes d'utilisation et compositions de r(-) fluoxetine | |
WO2002076461A1 (fr) | Combinaison de reboxetine et de citalopram | |
US20230248737A1 (en) | Compositions and methods for treating psychiatric disorders or symptoms thereof | |
CN118401239A (zh) | 用于治疗抑郁症,包括难治性抑郁症的2-氟脱氯氯胺酮 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20060410 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR |
|
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20070412 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20070824 |